327 related articles for article (PubMed ID: 34655497)
21. Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients.
Martial LC; Ter Heine R; Schouten JA; Hunfeld NG; van Leeuwen HJ; Verweij PE; de Lange DW; Pickkers P; Brüggemann RJ
Clin Pharmacokinet; 2017 Oct; 56(10):1197-1206. PubMed ID: 28144840
[TBL] [Abstract][Full Text] [Related]
22. Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC
Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetic/Pharmacodynamic Analysis of Voriconazole Against Candida spp. and Aspergillus spp. in Allogeneic Stem Cell Transplant Recipients.
Perez-Pitarch A; Guglieri-Lopez B; Ferriols-Lisart R; Pérez A; Ezquer-Garín C; Hernández-Boluda JC; Piñana JL; Navarro D; Solano C; Alós-Almiñana M
Ther Drug Monit; 2019 Dec; 41(6):740-747. PubMed ID: 31136417
[TBL] [Abstract][Full Text] [Related]
24. Dosing of caspofungin based on a pharmacokinetic/pharmacodynamic index for the treatment of invasive fungal infections in critically ill patients on continuous venovenous haemodiafiltration.
Pérez-Pitarch A; Ferriols-Lisart R; Aguilar G; Ezquer-Garín C; Belda FJ; Guglieri-López B
Int J Antimicrob Agents; 2018 Jan; 51(1):115-121. PubMed ID: 28666752
[TBL] [Abstract][Full Text] [Related]
25. Population pharmacokinetics of total and unbound concentrations of intravenous posaconazole in adult critically ill patients.
Sime FB; Byrne CJ; Parker S; Stuart J; Butler J; Starr T; Pandey S; Wallis SC; Lipman J; Roberts JA
Crit Care; 2019 Jun; 23(1):205. PubMed ID: 31171022
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic drug monitoring and safety of voriconazole therapy in patients with Child-Pugh class B and C cirrhosis: A multicenter study.
Wang T; Yan M; Tang D; Xue L; Zhang T; Dong Y; Zhu L; Wang X; Dong Y
Int J Infect Dis; 2018 Jul; 72():49-54. PubMed ID: 29793038
[TBL] [Abstract][Full Text] [Related]
27. Optimization of voriconazole dosage regimen to improve the efficacy in patients with invasive fungal disease by pharmacokinetic/pharmacodynamic analysis.
Chen L; Wang T; Wang Y; Yang Q; Xie J; Li Y; Lei J; Wang X; Xing J; Dong Y; Dong H
Fundam Clin Pharmacol; 2016 Oct; 30(5):459-65. PubMed ID: 27341147
[TBL] [Abstract][Full Text] [Related]
28. Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy.
Sandaradura I; Marriott DJE; Day RO; Norris RLG; Pang E; Stocker SL; Reuter SE
Eur J Clin Microbiol Infect Dis; 2021 Jul; 40(7):1521-1528. PubMed ID: 33638727
[TBL] [Abstract][Full Text] [Related]
29. Pharmacokinetic/Pharmacodynamic Target Attainment of Different Antifungal Agents in De-escalation Treatment in Critically Ill Patients: a Step toward Dose Optimization Using Monte Carlo Simulation.
Xie J; Yang Q; Han X; Dong Y; Zhang T; Li Y; Ji M; Liu C; Cai Y; Wang Y
Antimicrob Agents Chemother; 2022 Jun; 66(6):e0009922. PubMed ID: 35604209
[TBL] [Abstract][Full Text] [Related]
30. Population Pharmacokinetics Analysis and Dosing Simulations Of Meropenem in Critically Ill Patients with Pulmonary Infection.
Lan J; Wu Z; Wang X; Wang Y; Yao F; Zhao BX; Wang Y; Chen J; Chen C
J Pharm Sci; 2022 Jun; 111(6):1833-1842. PubMed ID: 35090867
[TBL] [Abstract][Full Text] [Related]
31. Population pharmacokinetics of voriconazole and CYP2C19 polymorphisms for optimizing dosing regimens in renal transplant recipients.
Lin XB; Li ZW; Yan M; Zhang BK; Liang W; Wang F; Xu P; Xiang DX; Xie XB; Yu SJ; Lan GB; Peng FH
Br J Clin Pharmacol; 2018 Jul; 84(7):1587-1597. PubMed ID: 29607533
[TBL] [Abstract][Full Text] [Related]
32. Voriconazole efficacy against Candida glabrata and Candida krusei: preclinical data using a validated in vitro pharmacokinetic/pharmacodynamic model.
Beredaki MI; Georgiou PC; Siopi M; Kanioura L; Arendrup MC; Mouton JW; Meletiadis J
J Antimicrob Chemother; 2020 Jan; 75(1):140-148. PubMed ID: 31665417
[TBL] [Abstract][Full Text] [Related]
33. Population Pharmacokinetics and Dosing Optimization of Gentamicin in Critically Ill Patients Undergoing Continuous Renal Replacement Therapy.
He S; Cheng Z; Xie F
Drug Des Devel Ther; 2022; 16():13-22. PubMed ID: 35023902
[TBL] [Abstract][Full Text] [Related]
34. Pharmacokinetics and safety of voriconazole intravenous-to-oral switch regimens in immunocompromised Japanese pediatric patients.
Mori M; Kobayashi R; Kato K; Maeda N; Fukushima K; Goto H; Inoue M; Muto C; Okayama A; Watanabe K; Liu P
Antimicrob Agents Chemother; 2015 Feb; 59(2):1004-13. PubMed ID: 25451051
[TBL] [Abstract][Full Text] [Related]
35. Current Ceftriaxone Dose Recommendations are Adequate for Most Critically Ill Children: Results of a Population Pharmacokinetic Modeling and Simulation Study.
Hartman SJF; Upadhyay PJ; Hagedoorn NN; Mathôt RAA; Moll HA; van der Flier M; Schreuder MF; Brüggemann RJ; Knibbe CA; de Wildt SN
Clin Pharmacokinet; 2021 Oct; 60(10):1361-1372. PubMed ID: 34036552
[TBL] [Abstract][Full Text] [Related]
36. Identification of factors influencing the pharmacokinetics of voriconazole and the optimization of dosage regimens based on Monte Carlo simulation in patients with invasive fungal infections.
Wang T; Chen S; Sun J; Cai J; Cheng X; Dong H; Wang X; Xing J; Dong W; Yao H; Dong Y
J Antimicrob Chemother; 2014 Feb; 69(2):463-70. PubMed ID: 24084636
[TBL] [Abstract][Full Text] [Related]
37. Caspofungin Weight-Based Dosing Supported by a Population Pharmacokinetic Model in Critically Ill Patients.
Märtson AG; van der Elst KCM; Veringa A; Zijlstra JG; Beishuizen A; van der Werf TS; Kosterink JGW; Neely M; Alffenaar JW
Antimicrob Agents Chemother; 2020 Aug; 64(9):. PubMed ID: 32660990
[TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics and safety of intravenous voriconazole - a novel wide-spectrum antifungal agent.
Purkins L; Wood N; Greenhalgh K; Eve MD; Oliver SD; Nichols D
Br J Clin Pharmacol; 2003 Dec; 56 Suppl 1(Suppl 1):2-9. PubMed ID: 14616407
[TBL] [Abstract][Full Text] [Related]
39. Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type.
Wang Y; Yao F; Chen S; Ouyang X; Lan J; Wu Z; Wang Y; Chen J; Wang X; Chen C
Drug Des Devel Ther; 2023; 17():2259-2271. PubMed ID: 37546521
[TBL] [Abstract][Full Text] [Related]
40. Population pharmacokinetics of fluconazole in liver transplantation: implications for target attainment for infections with Candida albicans and non-albicans spp.
Cojutti PG; Lugano M; Righi E; Della Rocca G; Bassetti M; Hope W; Pea F
Eur J Clin Pharmacol; 2018 Nov; 74(11):1449-1459. PubMed ID: 30032414
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
